Specifications and Dosage Guidelines for Bicizumab

Bimekizumab is a humanized IgG1 monoclonal antibody developed by UCB Pharma in Belgium. It targets two key inflammatory factors, IL-17A and IL-17F. It has shown a broader and faster skin damage control effect than traditional IL-17 single-target drugs in the treatment of plaque psoriasis. As an innovative biological drug, its mechanism is to dually inhibit the immune-inflammatory pathway by simultaneously neutralizing IL-17A and IL-17F, thereby significantly reducing skin hyperkeratosis and inflammatory response, and improving the clinical symptoms of psoriasis.

The current dosage form of bicizumab sold in the Chinese market is160mg/1.0ml prefilled syringe or syringe, each box contains 1 tube, for subcutaneous injection. In overseas markets such as the United States and Europe, the common specification is 160mg*2 tubes/box, which is mainly used for one-time dosage injection at the initial dose. The main method of use is subcutaneous injection. Patients can learn to inject themselves at home under the guidance of the hospital to improve treatment convenience and compliance.

According to the medication guide, the recommended usage of bicizumab is: 320 mg each time in the initial phase, administered at 0, 4, 8, 12 and 16 weeks respectively, and then every 8 weeks, 320 mg each time. For patients weighing 120kg or more, after the 16th week, 320mg should be administered every 4 weeks. The entire course of treatment will be adjusted by the doctor based on the condition and skin damage control effect. There is no need to use immunomodulatory drugs for pretreatment before treatment, but infection indicators, pulmonary tuberculosis screening, and basic liver and kidney functions should be regularly tested during use to ensure drug safety.

Compared with otherIL-17 drugs such as Secukinumab and Ixekizumab, Ixekizumab has more advantages in skin lesion clearance rate and response speed due to its dual-target design. In particular, the PASI90 or PASI100 compliance rate is higher, and it is suitable for moderate to severe patients pursuing rapid remission. At the same time, its dosing interval is longer, and the maintenance phase every two months is conducive to long-term management of patients' treatment plans.

Reference materials:https://www.drugs.com/bimekizumab.html